Scarica l'app Stockscreener
4.4649
0.40%
0.0149
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$4.45
Aprire:
$4.45
Volume 24 ore:
190.12K
Relative Volume:
0.14
Capitalizzazione di mercato:
$1.70B
Reddito:
$775.09M
Utile/perdita netta:
$-58.68M
Rapporto P/E:
-33.67
EPS:
-0.1326
Flusso di cassa netto:
$64.06M
1 W Prestazione:
+3.42%
1M Prestazione:
+0.17%
6M Prestazione:
-35.06%
1 anno Prestazione:
-31.27%
Intervallo 1D:
$4.39
$4.48
Intervallo di 1 settimana:
$4.305
$4.655
Portata 52W:
$3.82
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Confronta GDRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
4.465 | 1.70B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
217.61 | 35.48B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
52.81 | 9.82B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
84.28 | 7.09B | 1.15B | 96.70M | -161.99M | 1.09 |
|
TEM
Tempus Ai Inc
|
41.04 | 7.05B | 640.44M | -743.28M | -206.93M | -11.29 |
|
WAY
Waystar Holding Corp
|
36.80 | 6.27B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
Truist Cuts Price Target on GoodRx Holdings to $5.50 From $6.50, Keeps Hold Rating - MarketScreener
GoodRx Announces Date for First Quarter 2025 Earnings Release an - GuruFocus
GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call - Bluefield Daily Telegraph
GoodRx Sets Q1 Earnings Date: What Healthcare Investors Should Watch - Stock Titan
GoodRx Stock Tumbles Despite Launching New Retail Pharmacy Platform - Nasdaq
Levi & Korsinsky Notifies GoodRx Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineGDRX - ACCESS Newswire
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.18 Average Price Target from Brokerages - MarketBeat
GoodRx Stock Hits 52-Week Low at $4.09 Amid Market Challenges - Investing.com Australia
GoodRx Stock Hits 52-Week Low at $4.09 Amid Market Challenges By Investing.com - Investing.com South Africa
GoodRx (GDRX) Launches Digital Prescription Service with Hy-Vee - GuruFocus
GoodRx launches new e-commerce experience for prescriptions - Yahoo Finance
GoodRx Introduces New E-commerce Experience for Retail Pharmacies - Seeking Alpha
Allakos And 2 Other Promising Penny Stocks To Watch - simplywall.st
GoodRx Holdings: The Top 7 Influences on Its Performance for 2025 & the Future! - Smartkarma
GoodRx, PBM Price-Fixing MDL Set In Rhode Island - Law360
GoodRx Holdings (NASDAQ:GDRX) May Have Issues Allocating Its Capital - Yahoo Finance
Do Fundamentals Have Any Role To Play In Driving GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Stock Up Recently? - simplywall.st
GoodRx: Great Value For Patient Investors (Upgrade) (NASDAQ:GDRX) - Seeking Alpha
PBMs Hit With Antitrust Suit Over GoodRx Generics Program - Law360
GoodRx Strengthens Leadership: $100M Revenue Leader Takes President Role - StockTitan
GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Sold by US Bancorp DE - Defense World
GoodRx Holdings, Inc. (GDRX): Why Are Hedge Funds Bullish On This Cash-Rich Penny Stock? - Insider Monkey
GoodRx Holdings, Inc. (GDRX): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
12 Cash-Rich Penny Stocks To Buy According To Hedge Funds - Insider Monkey
Shareholders of GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your RightsGDRX - ACCESS Newswire
Wells Fargo & Company Cuts GoodRx (NASDAQ:GDRX) Price Target to $8.00 - Defense World
Levi & Korsinsky Notifies Shareholders of GoodRx Holdings, Inc.(GDRX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
GoodRx Holdings, Inc. (GDRX) Q4 Earnings Match Estimates - MSN
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q4 2024 Earnings Call Transcript - MSN
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc.(GDRX) Shareholders - ACCESS Newswire
The Analyst Verdict: GoodRx Holdings In The Eyes Of 4 Experts - Benzinga
Investors who lost money on GoodRx Holdings, Inc.(GDRX) should contact Levi & Korsinsky about pending Class ActionGDRX - ACCESS Newswire
GoodRx Holdings Leads The Charge With These 3 Promising Penny Stocks - Simply Wall St
Decoding GoodRx Holdings Inc (GDRX): A Strategic SWOT Insight - GuruFocus.com
GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales - Benzinga
GoodRx Holdings Inc (GDRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
GoodRx Holdings Reports Strong 2024 Financial Results - TipRanks
GoodRx Earnings Call: Growth Amid Challenges - TipRanks
Citi raises GoodRx stock target to $6.75, maintains buy rating By Investing.com - Investing.com South Africa
GoodRx Holdings IncOrdinary SharesClass A to Host Earnings Call - ACCESS Newswire
Citi raises GoodRx stock target to $6.75, maintains buy rating - Investing.com
Insights Into GoodRx (GDRX) Q4: Wall Street Projections for Key Metrics - MSN
Raymond James Reiterates Strong Buy Rating on GoodRx Holdings Inc. (GDRX) - StreetInsider.com
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):